At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
68Ga-DOTATATE PET/CTcombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
68Ga-DOTATATE PET for Localization of Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia
In Brief
A Phase 2 clinical trial evaluating 68Ga-DOTATATE PET/CT for Osteomalacia. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The researchers are trying to evaluate a newer imaging technique (Ga-DOTATATE PET/CT) to see if it is more sensitive to localize the source of the hormone, which has caused the low phosphate levels.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteomalacia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartJan 2019
Primary CompletionOct 2023
TodayJul 2026
First PostedNov 9, 2018
Enrollment StartJan 31, 2019
Primary CompletionOct 31, 2023
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 7.6 years ago
Interventions
68Ga-DOTATATE PET/CTcombination
Gallium-68 Dotatate, a radioactive imaging agent, is injected into a vein. Subjects will rest for approximately 50 minutes, after which approximately a 30 minute image of subjects body will be completed via PET/CT scan.